Biotinylated Human CD39 / ENTPD1 Protein, His,Avitag™ (MALS verified)

Source : 

Biotinylated Human CD39, His,Avitag (MALS verified) (CD9-H82E5) is expressed from human 293 cells (HEK293). It contains AA Thr 38 - Val 478 (Accession # P49961-1).

 

Molecule : CD39

 

Synonyms : CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1

 

Format : Liquid

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : N/A

 

Storage : -70℃

 

Shipping condition : Liquid,-70℃Dry ice

 

Molecular Weight : 54.0 kDa

 

Characteristics :

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag. The protein has a calculated MW of 54.0 kDa. The protein migrates as 66-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : 20 mM Tris, 150 mM NaCl, pH8.0

 

Description :

CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

 

References :

(1) Kaczmarek E, et al. 1996, J Biol Chem, 271(51):33116-22.
(2) Lima NF, et al. 2018, PLoS Negl Trop Dis., 12(3):e0006327.
(3) Bastid J, et al. 2013, Oncogene, 32(14):1743-51.